T Cell News and Research

Latest T Cell News and Research

CMS increases NLA for T-SPOT.TB test's CPT code 86481

Oxford Immunotec, Inc. announces that, following a reconsideration request made by the company, the Centers for Medicare and Medicaid Services has increased the national limitation amount (NLA) for the Current Procedural Terminology (CPT) code 86481 which is used for the T-SPOT.TB test.

10 Jan 2012

Cardio3BioSciences raises €3.1M in non-dilutive funding

The Belgian biotechnology company, Cardio3BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces it has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission's Seventh Framework Programme.

10 Jan 2012

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.

10 Jan 2012

Scientists can now observe enhancer activity in real embryo

As an embryo develops, different genes are turned on in different cells, to form muscles, neurons and other bodily parts. Inside each cell's nucleus, genetic sequences known as enhancers act like remote controls, switching genes on and off. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, can now see - and predict - exactly when each remote control is itself activated, in a real embryo.

10 Jan 2012

Researchers create prostate cancer drug delivery system

Honing chemotherapy delivery to cancer cells is a challenge for many researchers. Getting the cancer cells to take the chemotherapy "bait" is a greater challenge. But perhaps such a challenge has not been met with greater success than by the nanotechnology research team of Omid Farokhzad, MD, Brigham and Women's Hospital (BWH) Department of Anesthesiology Perioperative and Pain Medicine and Research.

10 Jan 2012

Urinary biomarkers can diagnose AKI in high-risk patients

Acute kidney injury (AKI) has severe consequences, with a 25 to 80 percent risk of in-hospital death. Researchers have found a way to diagnose AKI using a urine test, enabling emergency departments to identify these high-risk patients when they first arrive at the hospital.

10 Jan 2012

DHA plays an essential role in creating healthy sperm

Who knew that male fertility depends on sperm-cell architecture? A University of Illinois study reports that a certain omega-3 fatty acid is necessary to construct the arch that turns a round, immature sperm cell into a pointy-headed super swimmer with an extra long tail.

10 Jan 2012

Researchers uncover exact function of LARGE enzyme linked with MD

Researchers at the University of Iowa have worked out the exact function of an enzyme that is critical for normal muscle structure and is involved in several muscular dystrophies. The findings, which were published Jan. 6 in the journal Science,, could be used to develop rapid, large-scale testing of potential muscular dystrophy therapies.

10 Jan 2012

Study identifies netrin-1 as novel target for atherosclerosis

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries. The research, published online by Nature Immunology on January 8, 2012, explains why cholesterol-laden, coronary artery disease-causing cells called macrophages, accumulate in artery plaques.

10 Jan 2012

USPTO issues patent to Lixte's lead compounds for treatment of neurological diseases

Lixte Biotechnology Holdings announces that the United States Patent and Trademark Office awarded a patent for the use of lead compounds from each of two different types of drugs, protein phosphatase inhibitors and histone deacetylase inhibitors, for the potential prevention and treatment of neurodegenerative diseases.

9 Jan 2012

Neomatrix, UND partner to develop technology for early detection of breast cancer

The University of North Dakota and Neomatrix, LLC, have signed an exclusive agreement to develop technology for the early detection of breast cancer using the company's HALO Breast Pap Test device.

9 Jan 2012

Novel class of nanoparticles hold promise as a potential vehicle for drug delivery

In the images of fruit flies, clusters of neurons are all lit up, forming a brightly glowing network of highways within the brain. It’s exactly what University at Buffalo researcher Shermali Gunawardena was hoping to see: It meant that ORMOSIL, a novel class of nanoparticles, had successfully penetrated the insects’ brains. And even after long-term exposure, the cells and the flies themselves remained unharmed.

9 Jan 2012

Novel target in artery plaque identified as potential therapeutic intervention

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries.

9 Jan 2012

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences, Inc. announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.

9 Jan 2012

Houston bursts with customers for n3D's Bio-Assembler system

Houston, Texas, the home base of Rainbow Coral Corp.'s biosciences division, is bursting with potential customers for n3D's Bio-Assembler system. Just last month, the largest stem cell lab and bank in North America opened in Sugar Land, the city's fastest-growing suburb.

9 Jan 2012

BioCells opens new franchise headquartered in Campinas, Brazil

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that Biocordcell Argentina S.A. is opening a new franchise headquartered in Campinas, Brazil, a city of more than one million in the state of Sao Paulo.

9 Jan 2012

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

SFJ Pharma Ltd. II announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

9 Jan 2012